AstraZeneca UK Selects Dendrite to Provide Technology Platform to UK Sales Organization.

Business Editors/Health & Medical Writers

MORRISTOWN, N.J.--(BUSINESS WIRE)--Jan. 18, 2001

Dendrite International, Inc. today announced that they have been selected by AstraZeneca UK to provide the leading pharmaceutical company's UK sales organization with a comprehensive, technology-based communication and business planning platform designed to support its entire UK sales force. The contract calls for the full-scale implementation, training and on-going support of Dendrite's WebForce(TM) product suite, which will help expedite the transmission of information by linking over 900 representatives into a common sales force effectiveness (SFE) system for the first time. Dendrite is the leading provider of sales productivity solutions, analytics, data and sales support services for the worldwide pharmaceutical industry (NASDAQ/NMS:DRTE).

"After conducting a thorough review of the SFE products and services currently available, AstraZeneca UK ultimately chose Dendrite because of the Company's unique attributes which include a singular focus and understanding of the sales processes within the healthcare market combined with a proven delivery ability," said Angela Rees, Head of Business Information AstraZeneca UK.

"Additionally, by utilizing Dendrite's WebForce(TM) solution, AstraZeneca UK gets the benefit of having one partner for software, implementation and support, as well as the comfort of knowing that the initial platform established is flexible for developing future customer information based requirements," added Rees.

"Dendrite is pleased to have been selected as the company which will establish the SFE platform that AstraZeneca UK will be utilizing to continuously improve the effectiveness of its entire UK sales force," said John Bailye, chairman and CEO of Dendrite. "We will enjoy creating a sustained competitive edge for AstraZeneca."

About AstraZeneca

AstraZeneca (www.astrazeneca.com) is one of the world's leading pharmaceutical companies, providing innovative, effective products to fight disease in important areas of medical need. The company is research and technology intensive, with a focus on extensive international development and marketing acumen. The Company's business is focused on seven major therapeutic areas: cardiovascular, central nervous system, gastrointestinal, infection, oncology, pain control and anesthesia, and respiratory.

About Dendrite

Dendrite International, Inc. (NASDAQ/NMS:DRTE)(www.dendrite.com) designs and supports technology-based knowledge systems that enhance the competitive activities of the sales forces of the world's leading pharmaceutical companies. Over one-third of all pharmaceutical sales representatives and their managers worldwide rely on Dendrite.

Note to Editors: Dendrite is a registered trademark of Dendrite International, Inc.

This press release contains statements that are forward-looking statements and discuss expectations about future events or outcomes with respect to Dendrite and its business, including statements regarding expected results for future periods. We believe these statements are within the scope of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and we intend that these statements be covered by the safe harbors created by such acts. The forward-looking statements are based on our current expectations, assumptions, estimates and projections about our company and the pharmaceutical and consumer packaged goods industries and involve risks and uncertainties. Accordingly, Dendrite's actual results may differ materially from the results discussed in or implied by such forward-looking statements. The risk factors that could cause actual results to differ from the results expressed or implied by these forward-looking statements include the following: (i) our business is heavily dependent on the pharmaceutical industry; (ii) our quarterly results of operations may fluctuate significantly and may not meet market expectations; (iii) our lengthy sales and implementation cycles make it difficult to predict our quarterly revenues; (iv) our fixed costs may lead to fluctuations in our quarterly operating results if revenues fall below expectations; (v) our business is affected by variations in our customers' budget cycles; (vi) our revenues would decline and our business would be adversely affected by the loss of one of our major customers; (vii) we may be unable to successfully introduce new products or respond to technological change; (viii) timing of revenue recognition is dependent of many factors including timing of customer acceptance of product offerings and execution of contracts for Dendrite products, which factors are often outside the Company's control and which cannot always be predicted;(ix) increased competition may result in price reductions and decreased demand for our products and services; (x) some of our customers rely on our competitors for market data; (xi) our international operations have risks that our domestic operations do not; (xii) our success depends on retaining our key senior management team and on attracting and retaining qualified personnel; (xiii) our inability to manage our growth could adversely affect our business; (xiv) our business depends on proprietary technology that we may not be to protect completely; and (xv) the consumer packaged goods industry may have different characteristics from those we are used to in the pharmaceutical industry. In light of the significant uncertainties inherent in these forward-looking statements, you should not consider their inclusion as a representation by us or anyone else that we will achieve our objectives and plans. Moreover, we assume no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements. For further discussion of these and other factors that could adversely affect Dendrite's financial condition and results of operations consult Dendrite's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission.